Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol.14 , Issue 20s (2025)
https://www.jneonatalsurg.com

Targeting Diabetes-Associated Neurodegeneration: Neuroprotective Role of a Novel Antidiabetic Formulation

Rituraj Tripathi*[1], Dr. Lavakesh Kumar Omray[1], Dr. Naveen Gupta[1], Dr. Ganesh Prasad Patel[1], Mr. Hemant Agrawal[1]

[1]Patel College of Pharmacy, Madhyanchal Professional University, Bhopal, Madhya Pradesh, India.

***Corresponding Author:**
Rituraj Tripathi
Patel College of Pharmacy, Madhyanchal Professional University, Ratibad, Bhopal, Madhya Pradesh, India.
Email: tripathi.rituraj007@gmail.com

Cite this paper as: Rituraj Tripathi, Dr. Lavakesh Kumar Omray, Dr. Naveen Gupta, Dr. Ganesh Prasad Patel, Mr. Hemant Agrawal (2025) Targeting Diabetes-Associated Neurodegeneration: Neuroprotective Role of a Novel Antidiabetic Formulation. Journal of Neonatal Surgery, 14, (20s) 1041-1054

ABSTRACT

Diabetes mellitus is increasingly recognized not only as a metabolic disorder but also as a significant contributor to neurodegenerative changes in the central nervous system. Chronic hyperglycemia, insulin resistance, and associated metabolic disturbances have been closely linked with cognitive decline and an elevated risk of neurodegenerative conditions such as Alzheimer's disease. The concept of diabetes-associated neurodegeneration highlights the complex interplay between metabolic dysfunction and neuronal damage, involving mechanisms such as oxidative stress, neuroinflammation, mitochondrial impairment, and the accumulation of toxic protein aggregates. Despite advancements in antidiabetic therapies, conventional treatments primarily focus on glycemic control and often fail to address underlying neuronal damage. This has led to growing interest in the development of novel antidiabetic formulations with additional neuroprotective properties. Such formulations aim to target multiple pathological pathways simultaneously, offering improved therapeutic outcomes by reducing oxidative damage, modulating inflammatory responses, and enhancing neuronal survival. This review provides a comprehensive overview of the molecular mechanisms linking diabetes to neurodegeneration and critically evaluates the neuroprotective potential of emerging antidiabetic formulations. Furthermore, it highlights recent advances in drug delivery strategies and discusses current challenges and future perspectives in this evolving field. Understanding these interconnected mechanisms may pave the way for more effective therapeutic interventions aimed at preserving cognitive function in diabetic patients

Keywords: Diabetes mellitus; Neurodegeneration; Neuroprotection; Antidiabetic formulations; Oxidative stress; Insulin resistance; Neuroinflammation; Cognitive impairment

INTRODUCTION

Diabetes mellitus has emerged as one of the most prevalent chronic metabolic disorders worldwide, characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. While its classical complications, such as cardiovascular disease, nephropathy, and retinopathy, have been extensively studied, growing evidence suggests that diabetes also exerts profound effects on the central nervous system [1]. In recent years, increasing attention has been directed toward the concept of diabetes-associated neurodegeneration, which links metabolic dysregulation to progressive neuronal damage and cognitive decline [2]. The brain is a highly energy-demanding organ that relies on tightly regulated glucose metabolism for proper functioning. Disruption of insulin signaling and glucose homeostasis in diabetic conditions can impair neuronal survival, synaptic plasticity, and neurotransmitter balance [3]. This has led to the recognition of a "diabetic brain" phenotype, characterized by memory impairment, reduced cognitive performance, and an increased susceptibility to neurodegenerative disorders. Epidemiological and experimental studies have demonstrated a strong association between diabetes and conditions such as Alzheimer's disease, with some researchers even referring to Alzheimer's disease as "type 3 diabetes" due to shared molecular mechanisms [4]. At the molecular level, diabetes-associated neurodegeneration is driven by multiple interconnected pathways, including oxidative stress, chronic inflammation, mitochondrial dysfunction, and the accumulation of advanced glycation end products [5]. These factors collectively disrupt neuronal integrity and accelerate neurodegenerative processes. Despite significant progress in understanding these mechanisms, current therapeutic strategies remain largely focused on controlling blood glucose levels, often overlooking the underlying neuronal damage [6]. This gap in treatment has prompted the exploration of novel antidiabetic formulations that possess both glycemic control and neuroprotective properties. Such approaches aim to target multiple pathological pathways simultaneously, offering a more comprehensive strategy for preventing or slowing neurodegeneration in diabetic individuals. Advances in drug delivery systems and combination therapies have further enhanced the potential of these formulations to effectively reach and protect neural tissues [7–9]. The present review aims to provide a detailed analysis of the mechanisms underlying diabetes-associated neurodegeneration and to critically evaluate the emerging role of novel antidiabetic formulations in providing neuroprotection. By integrating current knowledge from molecular, experimental, and therapeutic perspectives, this study seeks to highlight potential strategies for improving neurological outcomes in diabetic patients.

2. Pathophysiology of Diabetes-Associated Neurodegeneration

Diabetes-associated neurodegeneration arises from a complex interplay of metabolic and molecular disturbances that progressively impair neuronal structure and function. Chronic hyperglycemia, a hallmark of diabetes, initiates a cascade of biochemical alterations that disrupt cellular homeostasis in the brain [10]. These alterations do not occur in isolation; rather, they are interconnected processes that collectively contribute to neuronal dysfunction, synaptic loss, and ultimately cognitive decline. The pathophysiology involves multiple overlapping mechanisms, including oxidative stress, impaired insulin signaling, neuroinflammation, and mitochondrial dysfunction, each playing a crucial role in the progression of neurodegenerative changes [11,12].

2.1 Hyperglycemia-Induced Oxidative Stress

Persistent hyperglycemia leads to excessive production of reactive oxygen species (ROS), primarily through mitochondrial overactivity and glucose auto-oxidation pathways. The accumulation of ROS results in oxidative stress, which damages cellular components such as lipids, proteins, and nucleic acids. Neurons are particularly vulnerable to oxidative damage due to their high metabolic activity and limited antioxidant defense systems [13]. Oxidative stress also disrupts cellular signaling pathways and promotes the activation of pro-apoptotic mechanisms, leading to neuronal cell death [13]. In addition, the formation of advanced glycation end products (AGEs) further amplifies oxidative damage by altering protein structure and function. This oxidative environment not only accelerates neuronal degeneration but also contributes to the impairment of synaptic plasticity, which is essential for learning and memory [14].

2.2 Insulin Resistance in the Brain

Insulin plays a critical role in the central nervous system, where it regulates neuronal survival, synaptic plasticity, and cognitive function. In diabetic conditions, insulin resistance extends beyond peripheral tissues and affects the brain, leading to impaired insulin signaling pathways [15,16]. This disruption reduces the activation of key signaling cascades involved in neuronal growth and survival, such as the PI3K/Akt pathway. As a result, neurons become more susceptible to stress and damage. Impaired insulin signaling also affects neurotransmitter regulation and synaptic function, contributing to cognitive deficits. So, reduced insulin activity has been linked to increased amyloid-beta accumulation, establishing a direct connection between diabetes and neurodegenerative disorders [17,18].

2.3 Neuroinflammation

Chronic low-grade inflammation is a prominent feature of diabetes and plays a significant role in neurodegeneration. Elevated levels of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukins, are commonly observed in diabetic conditions [19]. In the brain, these inflammatory mediators activate microglial cells, the resident immune cells of the central nervous system. While acute activation of microglia is protective, prolonged activation leads to the release of neurotoxic substances that exacerbate neuronal damage. Neuroinflammation also disrupts the blood-brain barrier, allowing peripheral inflammatory molecules to enter the brain and further amplify the inflammatory response. This sustained inflammatory environment contributes to progressive neuronal dysfunction and degeneration [20].

2.4 Mitochondrial Dysfunction

Mitochondria play a central role in cellular energy production and metabolic regulation. In diabetes, mitochondrial function is significantly impaired due to oxidative stress and metabolic imbalance [21]. This results in reduced ATP production, which is essential for neuronal activity and survival. Mitochondrial dysfunction also leads to increased production of ROS, creating a vicious cycle that further damages cellular components. Additionally, impaired mitochondrial dynamics, including altered fission and fusion processes, disrupt cellular homeostasis and promote apoptosis [22]. Pathophysiological Mechanisms in Diabetes are given in Table 1, Neuronal cells, which are highly dependent on mitochondrial energy, are particularly affected, leading to progressive loss of neuronal function.

Table 1: Pathophysiological Mechanisms in Diabetes-Associated Neurodegeneration [18,23]

Mechanism	Factors Involved	Impact on Neurons	Outcome
Oxidative Stress	ROS, AGEs	Cellular damage, apoptosis	Neuronal degeneration
Insulin Resistance	Impaired PI3K/Akt signaling	Reduced survival signaling	Cognitive dysfunction
Neuroinflammation	Cytokines, activated microglia	Neurotoxicity, BBB disruption	Progressive neuronal damage
Mitochondrial Dysfunction	Reduced ATP, increased ROS	Energy deficit, apoptosis	Loss of neuronal function

3. Molecular Mechanisms Underlying Neurodegeneration

The progression of neurodegeneration in diabetic conditions is governed by a series of interconnected molecular events that extend beyond general metabolic dysfunction. These mechanisms operate at the cellular and subcellular levels, influencing protein aggregation, neuronal signaling, and synaptic integrity [2,10]. While the broader pathophysiological processes such as oxidative stress and inflammation initiate neuronal damage, the downstream molecular alterations ultimately determine the severity and progression of neurodegeneration [24]. As summarized earlier in Table 1, multiple overlapping pathways contribute to neuronal dysfunction, and their combined effects accelerate cognitive decline in diabetic individuals.

3.1 Amyloid Beta Accumulation

One of the hallmark features of neurodegeneration, particularly in Alzheimer-like pathology, is the accumulation of amyloid beta (Aβ) peptides in the brain. In diabetic conditions, impaired insulin signaling plays a significant role in this process. Insulin-degrading enzyme (IDE), which normally facilitates the clearance of Aβ, becomes less effective when insulin levels are chronically elevated, leading to reduced degradation of amyloid peptides [25]. As a result, Aβ accumulates and aggregates into plaques that disrupt neuronal communication and induce oxidative stress. These aggregates interfere with synaptic function and trigger inflammatory responses, further exacerbating neuronal damage. The interplay between insulin resistance and amyloid accumulation highlights a critical link between metabolic dysfunction and classical neurodegenerative pathways [26].

3.2 Tau Protein Hyperphosphorylation

Tau proteins are essential for maintaining microtubule stability and neuronal structure. Under normal conditions, tau proteins undergo controlled phosphorylation; however, in diabetic states, abnormal kinase activity leads to excessive phosphorylation of tau. Hyperphosphorylated tau loses its ability to stabilize microtubules and instead forms neurofibrillary tangles, which are toxic to neurons [27]. This structural disruption impairs intracellular transport systems, affecting the movement of essential nutrients and organelles within neurons. Over time, this leads to neuronal dysfunction and cell death. The dysregulation of tau protein is closely associated with impaired insulin signaling pathways, further reinforcing the connection between diabetes and neurodegeneration [28].

3.3 Advanced Glycation End Products (AGEs)

Advanced glycation end products are formed through non-enzymatic reactions between glucose and proteins or lipids, a process that is significantly accelerated in hyperglycemic conditions. AGEs accumulate in various tissues, including the brain, where they alter the structure and function of proteins [29,30].

These modified molecules interact with specific receptors, such as RAGE (receptor for advanced glycation end products), triggering oxidative stress and inflammatory signaling pathways [31]. The activation of these pathways leads to increased production of reactive oxygen species and pro-inflammatory cytokines, creating a toxic environment for neurons. Additionally, AGEs can cross-link with structural proteins, reducing their flexibility and impairing cellular function. This contributes to the progressive decline in neuronal integrity observed in diabetic neurodegeneration.

3.4 Synaptic Dysfunction and Neurotransmitter Imbalance

Synaptic function is critical for effective neuronal communication and cognitive processes such as learning and memory. In diabetes-associated neurodegeneration, synaptic dysfunction emerges as an early and significant event. Impaired insulin signaling, oxidative stress, and inflammatory mediators collectively disrupt synaptic plasticity, leading to reduced efficiency of neuronal communication [2,7,32]. Neurotransmitter systems, including glutamate, acetylcholine, and dopamine, are particularly affected. For instance, altered glutamate signaling can lead to excitotoxicity, a condition in which excessive stimulation causes neuronal damage. Similarly, reduced acetylcholine levels are associated with memory impairment and cognitive decline [33,34].

In Addition to chemical signaling, structural changes at synapses, such as loss of dendritic spines, further compromise neuronal connectivity. These alterations ultimately impair neural network function, contributing to the cognitive deficits commonly observed in diabetic patients [35].

4. Current Antidiabetic Therapies and Their Limitation

4.1 Conventional Antidiabetic Drugs

A variety of antidiabetic agents are currently employed in clinical practice, each targeting specific aspects of glucose metabolism. Among these, biguanides such as Metformin are widely used due to their ability to enhance insulin sensitivity and reduce hepatic glucose production [36]. Although metformin has shown some beneficial effects on cellular metabolism, its direct role in neuroprotection remains limited and indirect. Insulin therapy remains essential, particularly in patients with advanced or uncontrolled diabetes. It effectively restores glucose homeostasis; however, its therapeutic action is largely confined to peripheral tissues [37]. Due to restricted penetration across the blood-brain barrier, insulin does not adequately address central nervous system dysfunction associated with diabetes. Sulfonylureas, which stimulate pancreatic insulin secretion, are also commonly prescribed. However, their mechanism of action is limited to glycemic control and does not extend to the modulation of neuronal damage or neuroinflammatory processes. Similarly, newer classes such as DPP-4 inhibitors and GLP-1 receptor agonists have shown some promise beyond glycemic regulation, particularly in experimental studies, but their clinical relevance in neuroprotection is still being explored [38,39].

4.2 Limitations of Conventional Therapies

Despite their widespread use, conventional antidiabetic therapies exhibit several limitations when evaluated from a neuroprotective perspective. One of the most significant challenges is their inability to effectively target the central nervous system [37]. The blood-brain barrier acts as a major obstacle, restricting the entry of many therapeutic agents and thereby limiting their action within neural tissues. In addition, these drugs are primarily designed to regulate blood glucose levels and do not directly address the molecular mechanisms responsible for neuronal damage, such as oxidative stress, inflammation, mitochondrial dysfunction, and protein aggregation [2]. As a result, even well-controlled diabetic patients may continue to experience progressive cognitive decline over time. Long-term use of certain antidiabetic drugs is also associated with adverse effects, including hypoglycemia, gastrointestinal disturbances, and weight fluctuations [40,41]. These factors can influence treatment adherence and overall patient outcomes. Furthermore, inter-individual variability in drug response suggests that current treatment strategies may not be equally effective for all patients, reinforcing the need for more targeted and personalized therapeutic approaches [42,43].

The comparative limitations and functional differences among commonly used antidiabetic drugs are summarized in **Table 2**, which highlights the gap between glycemic control and neuroprotective efficacy.

Table 2: Comparison of Conventional Antidiabetic Drugs and Their Neuroprotective Potential [7,44,45]

Drug Class	Example Drug	Primary Mechanism	Neuroprotective Potential	Limitation
Biguanides	Metformin	Improves insulin sensitivity	Moderate	Limited CNS targeting
Insulin Therapy	Insulin	Regulates blood glucose	Low	Poor blood-brain barrier penetration
Sulfonylureas	Glibenclamide	Stimulates insulin secretion	Low	No direct neuroprotective action
DPP-4 Inhibitors	Sitagliptin	Increases incretin levels	Emerging	Limited clinical evidence
GLP-1 Agonists	Liraglutide	Enhances insulin secretion	Promising	Requires further validation



Figure 1: Pathophysiological of Diabetes and Neurodegeneration

5. Novel Antidiabetic Formulations with Neuroprotective Potential

The limitations of conventional antidiabetic therapies have driven the development of novel formulations that extend beyond glycemic control to address the underlying mechanisms of neurodegeneration. These emerging strategies are designed to target multiple pathological pathways simultaneously, offering a more comprehensive approach to managing diabetes-associated neuronal damage [7,46]. By integrating metabolic regulation with neuroprotective actions, such formulations aim to preserve neuronal integrity, improve cognitive function, and potentially slow the progression of neurodegenerative changes. Unlike traditional therapies that primarily act on peripheral glucose metabolism, novel antidiabetic formulations are increasingly being engineered to enhance bioavailability, improve central nervous system targeting, and modulate key molecular pathways involved in neuronal survival. This shift toward multifunctional therapeutic design represents a significant advancement in the treatment of diabetes-related complications affecting the brain [47,48].

5.1 Mechanisms of Neuroprotection

The neuroprotective potential of novel antidiabetic formulations is largely attributed to their ability to intervene in multiple molecular pathways associated with neuronal damage. One of the primary mechanisms involves the reduction of oxidative stress through enhanced antioxidant activity. By scavenging reactive oxygen species and improving cellular redox balance, these formulations help prevent oxidative damage to neuronal cells [49].

Another critical mechanism is the modulation of inflammatory pathways. Many emerging formulations exhibit anti-inflammatory properties by suppressing the production of pro-inflammatory cytokines and inhibiting microglial activation. This contributes to a reduction in chronic neuroinflammation, which is a key driver of neurodegeneration. Improvement of insulin signaling within the brain also plays a vital role [50]. By restoring insulin sensitivity and activating downstream signaling pathways, these formulations enhance neuronal survival and synaptic plasticity. Additionally, some formulations have been shown to inhibit amyloid beta accumulation and tau hyperphosphorylation, thereby directly targeting processes associated with neurodegenerative disorders [51–54]. The key neuroprotective mechanisms targeted by these formulations are summarized in Table 3, highlighting their multi-targeted therapeutic potential.

5.2 Advanced Drug Delivery Strategies

A major challenge in developing neuroprotective therapies is the effective delivery of drugs to the brain. The presence of the blood-brain barrier significantly limits the penetration of many therapeutic agents, reducing their clinical effectiveness [55]. To overcome this limitation, advanced drug delivery systems have been developed to enhance brain targeting and improve drug bioavailability. Nanoparticle-based delivery systems have gained considerable attention due to their ability to encapsulate drugs and facilitate controlled release. These systems can be engineered to cross the blood-brain barrier, allowing for targeted delivery to neuronal tissues [56]. Similarly, liposomal formulations provide a protective environment for drugs, enhancing their stability and enabling efficient transport across biological barriers. Other innovative approaches include polymer-based carriers and intranasal delivery systems, which offer direct access to the brain while minimizing systemic side effects. These strategies not only improve drug delivery efficiency but also enhance the therapeutic potential of antidiabetic formulations in treating neurodegenerative conditions [57].

5.3 Emerging Therapeutic Approaches

In addition to synthetic drug formulations, there is growing interest in the use of natural compounds and combination therapies for neuroprotection. Herbal-based formulations, enriched with bioactive phytochemicals, have demonstrated antioxidant and anti-inflammatory properties that may complement conventional therapies [58,59]. These compounds often act on multiple molecular targets, making them suitable candidates for addressing complex conditions such as diabetes-associated neurodegeneration. Combination therapies, which involve the use of multiple agents with complementary mechanisms of action, are also being explored to enhance therapeutic outcomes [60]. By targeting different aspects of the disease simultaneously, these approaches may provide synergistic effects and improve overall efficacy. **The Mechanisms and Strategies of Novel Antidiabetic Formulations for Neuroprotection** are given in Table 3. The integration of novel formulations with advanced delivery systems and multi-target strategies represents a promising direction in the development of effective treatments for diabetic neurodegeneration [8,61].

Table 3: Mechanisms and Strategies of Novel Antidiabetic Formulations for Neuroprotection [2,62,63]

Approach	**Mechanism of Action**	**Neuroprotective Effect**	**Advantage**
Antioxidant-based	Reduces ROS and oxidative damage	Protects neuronal cells	Prevents cellular damage
Anti-inflammatory	Inhibits cytokines and microglial activation	Reduces neuroinflammation	Slows neurodegeneration
Insulin signaling enhancers	Improves neuronal insulin sensitivity	Enhances synaptic function	Improves cognitive performance
Nanoparticle delivery	Enhances brain targeting	Increases drug availability in CNS	Better therapeutic efficiency
Herbal formulations	Multi-target phytochemical action	Broad neuroprotective effects	Natural and less toxic



Figure 2: Mechanisms of Neuroprotection

6. Experimental and Preclinical Evidence

The development of novel antidiabetic formulations with neuroprotective potential is strongly supported by a growing body of experimental and preclinical studies. These investigations provide critical insights into the efficacy, mechanisms, and safety of emerging therapeutic strategies before their translation into clinical practice. Evidence from in vitro systems, animal models, and biomarker-based analyses collectively demonstrates the potential of these formulations to mitigate diabetes-associated neurodegeneration [64,65].

6.1 In Vitro Studies

In vitro studies have played a foundational role in understanding the cellular and molecular effects of antidiabetic formulations on neuronal systems. These studies typically utilize neuronal cell lines or primary neuronal cultures exposed to hyperglycemic conditions to mimic diabetic environments. Experimental findings indicate that novel formulations can significantly reduce oxidative stress by lowering intracellular reactive oxygen species levels and enhancing antioxidant enzyme activity [66]. Additionally, improvements in mitochondrial function and reductions in apoptotic signaling have been observed. Certain formulations have also demonstrated the ability to restore insulin signaling pathways and improve neuronal viability under stress conditions. These controlled cellular studies provide valuable mechanistic insights, although their limitations lie in the inability to fully replicate the complexity of in vivo systems [67].

6.2 Animal Models

Animal models of diabetes have been extensively used to evaluate the in vivo neuroprotective effects of antidiabetic formulations. Commonly used models include streptozotocin-induced diabetic rodents and genetically modified models that mimic insulin resistance and metabolic dysfunction. Preclinical studies in these models have demonstrated improvements in cognitive performance, particularly in learning and memory tasks [68]. Behavioral assessments, such as maze tests and object recognition tasks, have shown that treatment with novel formulations can reverse or slow cognitive decline associated with diabetes. At the molecular level, these studies report reduced neuroinflammation, decreased oxidative damage, and improved neuronal survival. Histological analyses further confirm reduced neuronal loss and preservation of brain structure. Importantly, advanced drug delivery systems have shown enhanced brain targeting, resulting in improved therapeutic outcomes compared to conventional formulations [69].

6.3 Observations from Preclinical Studies

The major findings from experimental and animal studies can be summarized as follows [69]:

Reduction in oxidative stress and restoration of antioxidant balance

Suppression of pro-inflammatory cytokine production

Improvement in insulin signaling within the brain

Decrease in amyloid beta accumulation and tau abnormalities

Enhancement of cognitive function and behavioral performance

Improved drug delivery across the blood-brain barrier

Table 4: Preclinical Evidence Supporting Neuroprotective Antidiabetic Formulations [28,70]

Study Type	**Model Used**	**Findings**	**Outcome**
In vitro	Neuronal cell cultures	Reduced ROS, improved mitochondrial function	Enhanced cell survival
In vivo (animal)	Diabetic rodent models	Improved cognition, reduced inflammation	Neuroprotection observed
Behavioral	Maze and memory tests	Improved learning and memory	Functional recovery
Molecular	Biomarker analysis	Reduced amyloid and tau pathology	Slowed neurodegeneration
Drug delivery	Nanoparticle-based systems	Increased brain targeting	Improved therapeutic efficacy



Figure 3: Experimental Models and Mechanisms of Neuroprotection

7. Clinical Implications and Translational Potential

The growing understanding of diabetes-associated neurodegeneration has significant clinical implications, particularly in the context of early diagnosis, therapeutic intervention, and long-term disease management. While preclinical studies provide strong evidence for the neuroprotective potential of novel antidiabetic formulations, translating these findings into clinical practice remains a critical challenge. Bridging this gap requires careful evaluation of efficacy, safety, and applicability in human populations [39,71].

7.1 Evidence from Human Studies

Although research in this area is still emerging, several clinical and observational studies suggest a potential link between antidiabetic therapies and improved neurological outcomes. Certain drug classes have demonstrated modest cognitive benefits, particularly in patients with well-controlled diabetes. However, most conventional therapies were not originally designed to target neurodegenerative pathways, which limits their overall effectiveness in addressing cognitive decline. Recent clinical investigations have begun to explore the role of newer formulations and combination therapies in improving brain function. Preliminary findings indicate that agents capable of modulating inflammation, oxidative stress, and insulin signaling may offer additional benefits beyond glycemic control. Despite these encouraging observations, large-scale and long-term clinical trials are still required to establish definitive therapeutic outcomes [72–74].

7.2 Therapeutic Challenges in Clinical Translation

The transition from experimental success to clinical application is often hindered by several challenges. One of the most significant barriers is the limited ability of therapeutic agents to effectively cross the blood-brain barrier, which restricts their access to target sites within the central nervous system. Another major challenge is the complexity of disease progression. Diabetes-associated neurodegeneration develops gradually and is influenced by multiple factors, including age, duration of diabetes, lifestyle, and genetic predisposition [8,10]. This variability makes it difficult to design standardized treatment protocols that are universally effective. In addition, concerns related to long-term safety and potential side effects must be carefully addressed. While novel formulations may show promising results in controlled experimental conditions, their safety profiles need to be validated in diverse patient populations before widespread clinical use [75].

7.3 Personalized and Precision Medicine Approaches

The future of managing diabetes-associated neurodegeneration lies in the adoption of personalized and precision medicine strategies. Given the heterogeneity in disease progression and treatment response, individualized therapeutic approaches are likely to yield better outcomes. Advances in biomarker research have opened new possibilities for early detection and targeted intervention. Biomarkers related to oxidative stress, inflammation, and neuronal damage can help identify patients at higher risk of cognitive decline, enabling timely therapeutic intervention. The clinical relevance of these approaches lies in their potential to enhance treatment efficacy while minimizing adverse effects, ultimately improving the quality of life for diabetic patients [76,77].

8. Challenges and Limitations

Despite significant progress in understanding diabetes-associated neurodegeneration and the development of novel antidiabetic formulations, several challenges continue to hinder their effective application in both research and clinical settings. These limitations arise from biological complexity, technical constraints, and gaps in translational research. Addressing these issues is essential for advancing therapeutic strategies and improving clinical outcomes. One of the primary challenges lies in the multifactorial nature of diabetes-associated neurodegeneration [10]. The condition is not driven by a single pathway but rather by the interaction of multiple mechanisms, including oxidative stress, inflammation, mitochondrial dysfunction, and impaired insulin signaling. This complexity makes it difficult to design therapies that can effectively target all contributing factors simultaneously. As a result, many treatments show partial efficacy, addressing certain aspects of the disease while leaving others unresolved [78,79].

Another significant limitation is the presence of the blood-brain barrier, which restricts the entry of therapeutic agents into the central nervous system. While advanced drug delivery systems have been developed to overcome this obstacle, their efficiency, stability, and long-term safety remain areas of concern. In many cases, insufficient drug concentration reaches the brain, limiting the overall therapeutic impact of otherwise promising formulations [80].

Variability in experimental models further complicates the interpretation of research findings. In vitro systems, although useful for mechanistic studies, do not fully replicate the complexity of living organisms. Similarly, animal models may not accurately represent human disease conditions due to physiological and genetic differences. This discrepancy often results in challenges when translating preclinical findings into successful clinical applications. Clinical translation itself presents additional hurdles [81,82]. The lack of large-scale, long-term clinical trials limits the availability of robust evidence supporting the neuroprotective efficacy of novel formulations. Furthermore, patient heterogeneity, including differences in age, disease duration, and comorbid conditions, makes it difficult to establish standardized treatment protocols. Safety and regulatory considerations also play a crucial role. Novel formulations, particularly those involving nanotechnology or combination therapies, require extensive evaluation to ensure they do not produce unintended side effects. Regulatory approval processes can be lengthy and complex, delaying the introduction of new therapies into clinical practice [83,84].

Table 5: Challenges and Limitations in Targeting Diabetes-Associated Neurodegeneration

Challenge	**Description**	**Clinical Use**	**Approach**
Disease Complexity	Multiple overlapping pathological pathways	Partial therapeutic effectiveness	Multi-target therapeutic strategies
Blood-Brain Barrier	Restricted drug penetration into CNS	Reduced drug efficacy	Advanced delivery systems (nanocarriers)
Model Limitations	Differences between in vitro, animal, and human systems	Poor translational accuracy	Improved and standardized models
Clinical Variability	Patient heterogeneity and disease progression differences	Inconsistent treatment outcomes	Personalized medicine approaches
Limited Clinical Data	Lack of large-scale human trials	Weak clinical validation	Conduct long-term clinical studies
Safety Concerns	Potential toxicity of novel formulations	Regulatory and ethical barriers	Rigorous safety assessment protocols

9. Future Perspectives

The field of diabetes-associated neurodegeneration is rapidly evolving, driven by advancements in molecular biology, pharmacology, and drug delivery technologies. While current research has established a strong link between metabolic dysfunction and neuronal damage, future efforts are expected to focus on developing more precise, targeted, and effective therapeutic strategies. The shift from symptom management to disease modification represents a key direction in this domain [85,86]. One of the most promising areas of future research is the development of multi-target therapeutic formulations. Given the complex and multifactorial nature of neurodegeneration in diabetes, single-target drugs are often insufficient to produce significant clinical benefits. Future formulations are likely to combine antioxidant, anti-inflammatory, and insulin-sensitizing properties within a single therapeutic platform. Such integrated approaches have the potential to simultaneously address multiple pathological pathways, thereby improving overall treatment efficacy. Advances in drug delivery systems are also expected to play a pivotal role in shaping future therapies. Overcoming the limitations imposed by the blood-brain barrier remains a major challenge, and innovative delivery strategies such as nanoparticle-based carriers, ligand-targeted systems, and intranasal routes are being actively explored [87]. These technologies aim to enhance drug penetration into the brain, increase bioavailability, and minimize systemic side effects, thereby improving therapeutic outcomes. Another important direction is the incorporation of natural bioactive compounds into antidiabetic formulations. Phytochemicals with known antioxidant and anti-inflammatory properties are gaining attention as potential adjuncts or alternatives to conventional drugs. Their ability to modulate multiple signaling pathways makes them particularly suitable for addressing complex conditions such as diabetes-associated neurodegeneration. Future studies are likely to focus on standardization, formulation optimization, and clinical validation of these compounds [88]. The integration of precision medicine into therapeutic strategies is also expected to transform disease management. Advances in genomics, proteomics, and biomarker discovery are enabling the identification of patient-specific disease profiles. This will allow the development of personalized treatment plans tailored to individual metabolic and genetic characteristics. Early diagnosis through reliable biomarkers may further facilitate timely intervention, potentially preventing or delaying the onset of neurodegenerative changes [89].

Emerging technologies such as artificial intelligence and computational modeling are also expected to contribute significantly to future research. These tools can be used to analyze complex biological data, predict drug responses, and optimize therapeutic design. By integrating experimental and computational approaches, researchers can accelerate the discovery and development of effective neuroprotective formulations. Despite these promising advancements, future research must also address existing challenges related to safety, scalability, and regulatory approval [90]. Ensuring the long-term safety of novel formulations, particularly those involving advanced delivery systems, will be critical for their successful clinical translation. Additionally, large-scale clinical trials will be necessary to validate efficacy and establish standardized treatment protocols. Overall, the future of targeting diabetes-associated neurodegeneration lies in the convergence of multidisciplinary approaches, combining molecular insights, innovative drug design, and personalized medicine. Continued research in this direction holds the potential to significantly improve therapeutic outcomes and enhance the quality of life for individuals affected by diabetes-related cognitive decline [85,91].

10. Conclusion

Diabetes-associated neurodegeneration represents a significant and often under-recognized complication of chronic metabolic dysfunction, linking impaired glucose homeostasis with progressive neuronal damage and cognitive decline. The underlying mechanisms involve a complex interplay of oxidative stress, insulin resistance, neuroinflammation, and mitochondrial dysfunction, all of which contribute to the deterioration of neuronal structure and function. Although conventional antidiabetic therapies are effective in controlling blood glucose levels, their limited ability to address central nervous system complications highlights the need for more targeted approaches. In this context, novel antidiabetic formulations with integrated neuroprotective properties offer a promising therapeutic strategy. By targeting multiple molecular pathways simultaneously and improving drug delivery to the brain, these formulations have the potential to overcome the limitations of existing treatments. Preclinical evidence supports the efficacy of such approaches in reducing neuronal damage and improving cognitive outcomes, although further clinical validation is required. Challenges related to drug delivery, safety, and translational applicability must be addressed to ensure successful implementation in clinical practice. In summary, advancing the understanding of diabetes-associated neurodegeneration and developing innovative, multi-targeted therapeutic strategies will be essential for improving neurological outcomes in diabetic patients. Continued research in this field holds significant potential for bridging the gap between metabolic control and neuroprotection, ultimately contributing to more comprehensive disease management

REFERENCES

[1] Benatti C, Blom JMC, Rigillo G, Alboni S, Zizzi F, Torta R, et al. Disease-Induced Neuroinflammation and Depression. CNS & Neurological Disorders - Drug Targets 2016;15:414. https://doi.org/10.2174/1871527315666160321104749.

[2] Huai J, Chang E-S, Zhu Y, Ma W, Lv T, Sun J, et al. Diabetic encephalopathy: metabolic reprogramming as a potential driver of accelerated brain aging and cognitive decline. Frontiers in Cell and Developmental Biology 2025;13:1701406. https://doi.org/10.3389/fcell.2025.1701406.

[3] Zhao W, Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2008;1792:482. https://doi.org/10.1016/j.bbadis.2008.10.014.

[4] Santiago JA, Karthikeyan MG, Lackey M, Villavicencio D, Potashkin JA. Diabetes: a tipping point in neurodegenerative diseases. Trends in Molecular Medicine 2023;29:1029. https://doi.org/10.1016/j.molmed.2023.09.005.

[5] Domínguez RO, Marschoff ER, González S, Repetto MG, Serra JA. Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients. Diabetes Research and Clinical Practice 2012;98:68. https://doi.org/10.1016/j.diabres.2012.05.013.

[6] Rajamani U. Causes of Neurodegeneration in Diabetes: Possible Culprits and Therapeutic Targets. Brain Disorders & Therapy 2014;3. https://doi.org/10.4172/2168-975x.1000130.

[7] Chen X, Huang Y, Xiong X. Mechanisms underlying cognitive impairment and management strategies in type 2 diabetes. Frontiers in Endocrinology 2025;16:1655768. https://doi.org/10.3389/fendo.2025.1655768.

[8] Yang Y, Zhao B, Wang Y, Lan HH, Liu X, Hu Y, et al. Diabetic neuropathy: cutting-edge research and future directions. Signal Transduction and Targeted Therapy 2025;10:132. https://doi.org/10.1038/s41392-025-02175-1.

[9] Yorek MA. Combination therapy is it in the future for successfully treating peripheral diabetic neuropathy? Frontiers in Endocrinology 2024;15. https://doi.org/10.3389/fendo.2024.1357859.

[10] Llorián-Salvador M, Cabeza-Fernández S, Gomez-Sanchez JA, Fuente AG de la. Glial cell alterations in diabetes-induced neurodegeneration. Cellular and Molecular Life Sciences 2024;81:47. https://doi.org/10.1007/s00018-023-05024-y.

[11] Tzioras M, McGeachan RI, Durrant CS, Spires-Jones TL. Synaptic degeneration in Alzheimer disease. Nature Reviews Neurology 2022;19:19. https://doi.org/10.1038/s41582-022-00749-z.

[12] Hein ZM, Karikalan B, Gopalakrishna PK, Dhevi K, Alkatiri A, Hussan F, et al. Toward a Unified Framework in Molecular Neurobiology of Alzheimer's Disease: Revisiting the Pathophysiological Hypotheses. Molecular Neurobiology 2025;63:282. https://doi.org/10.1007/s12035-025-05602-0.

[13] Ebding J, Mazzone F, Kins S, Pielage J, Maritzen T. How neurons cope with oxidative stress. Biological Chemistry 2025;406:219. https://doi.org/10.1515/hsz-2024-0146.

[14] Asadbegi M, Komaki A, Amiri P, Karimi SA, Yaghmaei P, Ebrahim-Habibi A, et al. Learning and Memory Impairment Induced by Amyloid Beta Peptide and Effects of Thymol on Hippocampal Synaptic Plasticity in Rats Fed a High-Fat Diet That Received Amyloid Beta. IntechOpen eBooks, IntechOpen; 2023. https://doi.org/10.5772/intechopen.110416.

[15] Wang S, Shi Y, Xin R, Kang H, Xiong H, Ren J. Exploring the role of insulin resistance in bridging the metabolic syndrome and Alzheimer's disease-a review of mechanistic studies. Frontiers in Endocrinology 2025;16. https://doi.org/10.3389/fendo.2025.1614006.

[16] Gulyaeva NV. Glucocorticoids Orchestrate Adult Hippocampal Plasticity: Growth Points and Translational Aspects. Biochemistry (Moscow) 2023;88:565. https://doi.org/10.1134/s0006297923050012.

[17] Ni W, Liu WV, Li M, Wei S, Xu X, Huang S, et al. Altered brain functional network connectivity and topology in type 2 diabetes mellitus. Frontiers in Neuroscience 2025;19. https://doi.org/10.3389/fnins.2025.1472010.

[18] Luo J-S, Ning J, Chen Z-Y, Li W, Zhou R, Yan R, et al. The Role of Mitochondrial Quality Control in Cognitive Dysfunction in Diabetes. Neurochemical Research 2022;47:2158. https://doi.org/10.1007/s11064-022-03631-y.

[19] Li H, Ren J, Li Y, Wu Q, Wei J. Oxidative stress: The nexus of obesity and cognitive dysfunction in diabetes. Frontiers in Endocrinology 2023;14. https://doi.org/10.3389/fendo.2023.1134025.

[20] Adamu A, Li S, Gao F, Xue G. The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets. Frontiers in Aging Neuroscience 2024;16. https://doi.org/10.3389/fnagi.2024.1347987.

[21] Chen YH, Liu Y, Liu Y, Li Y, Li D, Mei Z, et al. Mitochondrial quality control in diabetes mellitus and complications: molecular mechanisms and therapeutic strategies. Cell Death and Disease 2025;16. https://doi.org/10.1038/s41419-025-07936-y.

[22] Li R, Wang L, Duan H, Zhang Q, Guo X, Wu C, et al. Regulation of mitochondrial dysfunction induced cell apoptosis is a potential therapeutic strategy for herbal medicine to treat neurodegenerative diseases. Frontiers in Pharmacology 2022;13. https://doi.org/10.3389/fphar.2022.937289.

[23] Chavda V, Yadav D, Patel S, Song M. Effects of a Diabetic Microenvironment on Neurodegeneration: Special Focus on Neurological Cells. Brain Sciences 2024;14:284. https://doi.org/10.3390/brainsci14030284.

[24] Aranda-Abreu GE, Rojas-Durán F, Hernández-Aguilar ME, Herrera-Covarrubias D, Tlapa-Monge LR, Gutiérrez S. The Molecular Architecture of Neurodegeneration: An Integrative Overview of Convergent Mechanisms. NeuroSci 2026;7:7. https://doi.org/10.3390/neurosci7010007.

[25] Tyagi A, Musa M, Labeikovsky W, Pugazhenthi S. Sirt3 deficiency induced down regulation of insulin degrading enzyme in comorbid Alzheimer's disease with metabolic syndrome. Scientific Reports 2022;12. https://doi.org/10.1038/s41598-022-23652-5.

[26] Albaik M, Saleh DS, Kauther D, Mohammed H, Alfarra S, Alghamdi A, et al. Bridging the gap: glucose transporters, Alzheimer's, and future therapeutic prospects. Frontiers in Cell and Developmental Biology 2024;12. https://doi.org/10.3389/fcell.2024.1344039.

[27] Dias-Carvalho A, Sá SI, Carvalho F, Fernandes E, Costa VM. Inflammation as common link to progressive neurological diseases. Archives of Toxicology 2023;98:95. https://doi.org/10.1007/s00204-023-03628-8.

[28] Raza A, Saleem S, Imran SS, Rahman S, Haroon M, Razzaq A, et al. From metabolic dysregulation to neurodegenerative pathology: the role of hyperglycemia, oxidative stress, and blood-brain barrier breakdown in T2D-driven Alzheimer's disease. Metabolic Brain Disease 2025;40. https://doi.org/10.1007/s11011-025-01700-z.

[29] Singh S, Singh S, Saw S, Rathi S, Sharma B. Single Cell Transcriptomics of Traditional Chinese Medicine Bioactives: Mapping Immune, Neural and Hepatic Responses. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2025 Nov 10;41:e20250028. doi: 10.62958/j.cjap.2025.028. PMID: 41207694.

[30] Zahra HA. Advanced glycation end products and human diseases. Journal of Biological Research - Bollettino Della Società Italiana Di Biologia Sperimentale 2025. https://doi.org/10.4081/jbr.2025.12656.

[31] Khalid M, Petroianu G, Adem A. Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and

Perspectives. Biomolecules 2022;12:542. https://doi.org/10.3390/biom12040542.

[32] Chomová M. Toward the Decipherment of Molecular Interactions in the Diabetic Brain. Biomedicines 2022;10:115. https://doi.org/10.3390/biomedicines10010115.

[33] Wiesman AI, Gallego-Rudolf J, Villeneuve S, Baillet S, Wilson TW. Alignments between cortical neurochemical systems, proteinopathy and neurophysiological alterations along the Alzheimer's disease continuum. medRxiv (Cold Spring Harbor Laboratory) 2024. https://doi.org/10.1101/2024.04.13.24305551.

[34] Zheng Q, Lu Y, Yu D, Zhao L, Wang Y, Chen P, et al. Spatial metabolomics reveals the effects of Acanthopanax senticosus on region-specific alterations in neurotransmitters and metabolites levels in the brains of α-syn transgenic Parkinson's disease model mice. Metabolic Brain Disease 2025;40. https://doi.org/10.1007/s11011-025-01673-z.

[35] Aggarwal A, Yadav B, Sharma N, Kaur R, Rishi V. Unraveling epigenetic mechanisms causing cognitive dysfunction in experimental diabetes. Research Square (Research Square) 2023. https://doi.org/10.21203/rs.3.rs-2466100/v1.

[36] Rajalingam4 RVS M Gowtham2, S Arunagiri2, S Mahalakshmi2, N Gnanasekar3, D. Metformin: A Comprehensive Clinical and Pharmacological Review of Its Spectrum, Efficacy, Resistance, and Safety Profile. Open MIND 2026. https://doi.org/10.5281/zenodo.18484163.

[37] Mirzadeh Z, Faber CL, Schwartz MW. Central Nervous System Control of Glucose Homeostasis: A Therapeutic Target for Type 2 Diabetes? The Annual Review of Pharmacology and Toxicology 2022;62:55. https://doi.org/10.1146/annurev-pharmtox-052220-010446.

[38] Helal MM, AbouShawareb H, Abbas O, Haddad R, Zain YE, Osman AM, et al. GLP-1 receptor agonists in Parkinson's disease: an updated comprehensive systematic review with meta-analysis. Diabetology & Metabolic Syndrome 2025;17. https://doi.org/10.1186/s13098-025-01888-1.

[39] Colin IM, Szczepanski LW, Gérard A, Elosegi J-A. Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer's Disease. touchREVIEWS in Endocrinology 2023;19:16. https://doi.org/10.17925/ee.2023.19.1.16.

[40] Min SH. Association between Type 2 Diabetes Mellitus and Brain Atrophy: A Meta-Analysis (Diabetes Metab J 2022;46:781-802). Diabetes & Metabolism Journal 2022;46:813. https://doi.org/10.4093/dmj.2022.0259.

[41] Lin Y, Gong Z, Ma C, Wang Z, Wang K. Relationship between glycemic control and cognitive impairment: A systematic review and meta-analysis. Frontiers in Aging Neuroscience 2023;15. https://doi.org/10.3389/fnagi.2023.1126183.

[42] Olson AW, Brown JT. How Pharmacogenomics Informs and Influences the Medication Experience. INNOVATIONS in Pharmacy 2024;14:7. https://doi.org/10.24926/iip.v14i4.5796.

[43] Marques-Garcia F, Martinez-Bravo C. A review of pharmacogenomics in the individualization of pharmacological treatment: present and future. Journal of Laboratory and Precision Medicine 2026;11:6. https://doi.org/10.21037/jlpm-25-9.

[44] Kostrzewska P, Kuca P, Witek P, Małyszko J, Alster NM, Alster P. SGLT-2 Inhibitors in the Prevention and Progression of Neurodegenerative Diseases: A Narrative Review. Neurology and Therapy 2025. https://doi.org/10.1007/s40120-025-00832-9.

[45] Ogura J, Yamaguchi H. The Effectiveness of Antidiabetic Drugs in Treating Dementia: A Peek into Pharmacological and Pharmacokinetic Properties. International Journal of Molecular Sciences 2022;23:6542. https://doi.org/10.3390/ijms23126542.

[46] Wolf V, Abdul Y, Ergul A. Novel Targets and Interventions for Cognitive Complications of Diabetes. Frontiers in Physiology 2022;12:815758. https://doi.org/10.3389/fphys.2021.815758.

[47] Liu N, Ruan J, Li H, Fu J-H. Nanoparticles loaded with natural medicines for the treatment of Alzheimer's disease. Frontiers in Neuroscience 2023;17. https://doi.org/10.3389/fnins.2023.1112435.

[48] DS Rajput, M Bhoi, S. Singh, Comment on Fennel essential oil and its nanoemulsion modulate macrophage-mediated inflammatory responses and promote pressure ulcer healing. International Immunopharmacology. 2026; 173:116184. https://doi.org/10.1016/j.intimp.2026.116184

[49] Liberto VD, Mudò G. Role of Bioactive Molecules on Neuroprotection, Oxidative Stress, and Neuroinflammation Modulation. International Journal of Molecular Sciences 2022;23:15925. https://doi.org/10.3390/ijms232415925.

[50] Kip E, Parr-Brownlie LC. Healthy lifestyles and wellbeing reduce neuroinflammation and prevent neurodegenerative and psychiatric disorders. Frontiers in Neuroscience 2023;17. https://doi.org/10.3389/fnins.2023.1092537.

[51] Rizvi SMD, Hussain T, Mehmood K, Moin A, Alanazi AS, Subaiea GM. Molecular docking and dynamic simulation study to explore quercetin as a multi-potent candidate against gliomas. Tropical Journal of Pharmaceutical Research 2022;20:815. https://doi.org/10.4314/tjpr.v20i4.23.

[52] Li X, Zhang X, Wang T, Li H, Li Y, Liu J, et al. Sinomenine in cerebral ischemia: mechanisms, delivery strategies, and the emerging multifunctional biomaterials of the bone–brain axis. Frontiers in Medicine 2025;12.

https://doi.org/10.3389/fmed.2025.1677685.

[53] Nabizadeh F. Neuroprotective role of Fisetin in Alzheimer’s disease: An overview of potential mechanism and clinical findings. Neurology Letters 2024;3:14. https://doi.org/10.61186/nl.3.2.14.

[54] Lai Z, Ke L, Zhao W. Naringenin as a neurotherapeutic agent in Alzheimer’s disease: epigenetic signatures, gut microbiota alterations, and molecular neuroprotection. Frontiers in Aging Neuroscience 2025;17. https://doi.org/10.3389/fnagi.2025.1647967.

[55] Qu Z, Luo J, Li Z, Yang R, Zhao J, Chen X, et al. Advancements in strategies for overcoming the blood–brain barrier to deliver brain-targeted drugs. Frontiers in Aging Neuroscience 2024;16:1353003. https://doi.org/10.3389/fnagi.2024.1353003.

[56] Mittal K, Pharasi N, Sarna B, Singh M, Rachana R, Haider S, et al. Nanotechnology-based drug delivery for the treatment of CNS disorders. Translational Neuroscience 2022;13:527. https://doi.org/10.1515/tnsci-2022-0258.

[57] Zhang X, Fu M, Wang Y, Wu T. Strategies for delivering drugs across the blood-brain barrier for the treatment of neurodegenerative diseases. Frontiers in Drug Delivery 2025;5. https://doi.org/10.3389/fddev.2025.1644633.

[58] Li Z, Yang J, Yu-hua Y, Yang M, Juan Y, Yu C, et al. Bioactive compounds in Chinese herbal medicine: anti-inflammatory mechanisms targeting neurological disorders. Frontiers in Nutrition 2025;12:1646438. https://doi.org/10.3389/fnut.2025.1646438.

[59] Lim DW, Lee J, Lee C-H, Kim YT. Natural Products and Their Neuroprotective Effects in Degenerative Brain Diseases: A Comprehensive Review. International Journal of Molecular Sciences 2024;25:11223. https://doi.org/10.3390/ijms252011223.

[60] Vear A, Heneka MT, Clemmensen C. Incretin-based therapeutics for the treatment of neurodegenerative diseases. Nature Metabolism 2025;7:679. https://doi.org/10.1038/s42255-025-01263-4.

[61] Meng X, Zhang H, Zhao Z, Li S, Zhang X, Guo R, et al. Type 3 diabetes and metabolic reprogramming of brain neurons: causes and therapeutic strategies. Molecular Medicine 2025;31:61. https://doi.org/10.1186/s10020-025-01101-z.

[62] Ayoub S, Arabi M, Al-Najjar Y, Laswi I, Outeiro TF, Châari A. Glycation in Alzheimer’s Disease and Type 2 Diabetes: The Prospect of Dual Drug Approaches for Therapeutic Interventions. Molecular Neurobiology 2025;62:14859. https://doi.org/10.1007/s12035-025-05051-9.

[63] Miyashita A, Kobayashi M, Yokota T, Zochodne DW. Diabetic Polyneuropathy: New Strategies to Target Sensory Neurons in Dorsal Root Ganglia. International Journal of Molecular Sciences 2023;24:5977. https://doi.org/10.3390/ijms24065977.

[64] Su J, Sun G, An J, Ao Y, Li J, Shen Z, et al. Efficacy and safety of the integration of traditional Chinese medicine and western medicine in the treatment of diabetes-associated cognitive decline: a systematic review and meta-analysis. Frontiers in Pharmacology 2023;14. https://doi.org/10.3389/fphar.2023.1280736.

[65] Andrei C, Șeremet OC, Pușcașu C, Zanfirescu A. Translating Basic Science to Clinical Applications: A Narrative Review of Repurposed Pharmacological Agents in Preclinical Models of Diabetic Neuropathy. Biomedicines 2025;13:1709. https://doi.org/10.3390/biomedicines13071709.

[66] Schiano E, Novellino E, Fernández MMG, Lorinczova HT, Tenore GC, Iannuzzo F, et al. Antioxidant and Antidiabetic Properties of a Thinned-Nectarine-Based Nanoformulation in a Pancreatic β-Cell Line. Antioxidants 2023;13:63. https://doi.org/10.3390/antiox13010063.

[67] Linden RJ van der, Gerritsen J, Liao M-C, Widomska J, Pearse RV, White FM, et al. RNA-binding protein ELAVL4/HuD ameliorates Alzheimer’s disease-related molecular changes in human iPSC-derived neurons. Progress in Neurobiology 2022;217:102316. https://doi.org/10.1016/j.pneurobio.2022.102316.

[68] García-Magro N, Mesa-Lombardo A, Barros-Zulaica N, Núñez Á. Impairment of synaptic plasticity in the primary somatosensory cortex in a model of diabetic mice. Frontiers in Cellular Neuroscience 2024;18. https://doi.org/10.3389/fncel.2024.1444395.

[69] Venkatesh U. Advanced Drug Delivery For Alzheimer’s Disease Using Targeted Nanoparticles Across The Blood-Brain Barrier. African Journal of Biomedical Research 2024:1805. https://doi.org/10.53555/ajbr.v27i3s.1710.

[70] Wang X-C, Chu C-L, Li H, Lu K, Liu C-J, Cai Y, et al. Efficacy and safety of hypoglycemic drugs in improving cognitive function in patients with Alzheimer’s disease and mild cognitive impairment: A systematic review and network meta-analysis. Frontiers in Neurology 2022;13. https://doi.org/10.3389/fneur.2022.1018027.

[71] Dou X, Zhao L, Li J, Jiang Y. Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus. Frontiers in Neuroscience 2025;19. https://doi.org/10.3389/fnins.2025.1537898.

[72] Balogh D, Wagner L, Fekete A. An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis. International Journal of Molecular Sciences 2023;24:7789. https://doi.org/10.3390/ijms24097789.

[73] Liu J, Pan S, Wang X, Liu Z, Zhang Y. Role of advanced glycation end products in diabetic vascular injury: molecular mechanisms and therapeutic perspectives. European Journal of Medical Research 2023;28. https://doi.org/10.1186/s40001-023-01431-w.

[74] Uçar K, Kopuz TNY. Therapeutic prospects of phytochemicals in diabetes: insights from recent clinical evidence. Endokrynologia Polska 2025;76:586. https://doi.org/10.5603/ep.107193.

[75] Lee CS, Kulkarni YA, Pierre V, Maski M, Wanner C. Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review. BioDrugs 2024;38:795. https://doi.org/10.1007/s40259-024-00684-z.

[76] Jiang Y, Liu X, Gao H, Yan J, Cao Y. A new nomogram model for the individualized prediction of mild cognitive impairment in elderly patients with type 2 diabetes mellitus. Frontiers in Endocrinology 2024;15. https://doi.org/10.3389/fendo.2024.1307837.

[77] Ehtewish H, Arredouani A, El-Agnaf OMA. Diagnostic, Prognostic, and Mechanistic Biomarkers of Diabetes Mellitus-Associated Cognitive Decline. International Journal of Molecular Sciences 2022;23:6144. https://doi.org/10.3390/ijms23116144.

[78] Ding W, Yang X, Lai K, Jiang Y, Liu Y. The potential of therapeutic strategies targeting mitochondrial biogenesis for the treatment of insulin resistance and type 2 diabetes mellitus. Archives of Pharmacal Research 2024;47:219. https://doi.org/10.1007/s12272-024-01490-5.

[79] Chandrasekaran P, Weiskirchen R. Cellular and Molecular Mechanisms of Insulin Resistance. Current Tissue Microenvironment Reports 2024;5:79. https://doi.org/10.1007/s43152-024-00056-3.

[80] Teng X-Q, Qu J, Li G, Zhuang H-H, Qu Q. Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery. Frontiers in Cell and Developmental Biology 2022;10. https://doi.org/10.3389/fcell.2022.824299.

[81] Härtung T. The (misleading) role of animal models in drug development. Frontiers in Drug Discovery 2024;4. https://doi.org/10.3389/fddsv.2024.1355044.

[82] Frangogiannis NG. Why animal model studies are lost in translation. The Journal of Cardiovascular Aging 2022;2. https://doi.org/10.20517/jca.2022.10.

[83] Herdiana Y. Bridging the Gap: The Role of Advanced Formulation Strategies in the Clinical Translation of Nanoparticle-Based Drug Delivery Systems. International Journal of Nanomedicine 2025:13039. https://doi.org/10.2147/ijn.s554821.

[84] Nwankwo EI, Emeihe EV, Ajegbile MD, Olaboye JA, Maha CC. Innovative drug delivery methods for combating antimicrobial resistance. International Medical Science Research Journal 2024;4:834. https://doi.org/10.51594/imsrj.v4i8.1454.

[85] Smith ADT, Moreno-Castellanos N, Rodríguez JA, Marín-Loaiza JC, Bustos G. Evaluating the Antitumor Potential of Cannabichromene, Cannabigerol, and Related Compounds from Cannabis sativa and Piper nigrum Against Malignant Glioma: An In Silico to In Vitro Approach. International Journal of Molecular Sciences 2025;26:5688. https://doi.org/10.3390/ijms26125688.

[86] Bach D-H, Nguyen TTN. Immunometabolism Reframes Alzheimer’s Disease: From Systemic Dysmetabolism to Glial Rewiring. Cellular and Molecular Neurobiology 2026;46. https://doi.org/10.1007/s10571-026-01691-0.

[87] Kulkarni M, Patel K, Patel A, Patel S, Desai J, Patel M, et al. Nanomaterials as drug delivery agents for overcoming the blood-brain barrier: A comprehensive review. ADMET & DMPK 2023. https://doi.org/10.5599/admet.2043.

[88] Adem MA, Decourt B, Sabbagh MN. Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer’s Disease. Biomedicines 2024;12:99. https://doi.org/10.3390/biomedicines12010099.

[89] Hällqvist J, Bartl M, Dakna M, Schade S, Garagnani P, Bacalini M-G, et al. Plasma proteomics identify biomarkers predicting Parkinson’s disease up to 7 years before symptom onset. Nature Communications 2024;15:4759. https://doi.org/10.1038/s41467-024-48961-3.

[90] Bankar AA, Nagulwar V, Kotagale N, Inamdar N. Neuroprotective prospectives of triterpenoids. Exploration of Neuroscience 2024;3:231. https://doi.org/10.37349/en.2024.00047.

[91] Novaković SB, Jakovljević V, Jović N, Andrić K, Milinković M, Anicic T, et al. Exploring the Antioxidative Effects of Ginger and Cinnamon: A Comprehensive Review of Evidence and Molecular Mechanisms Involved in Polycystic Ovary Syndrome (PCOS) and Other Oxidative Stress-Related Disorders. Antioxidants 2024;13:392. https://doi.org/10.3390/antiox13040392..